Literature DB >> 10215658

Inhibition and stimulation of long-chain fatty acid oxidation by chloroacetaldehyde and methylene blue in rats.

T M Visarius1, J W Stucki, B H Lauterburg.   

Abstract

The effects of chloroacetaldehyde (CAA) and methylene blue, both alone and together, on mitochondrial metabolism, hepatic glutathione content, and bile flow were investigated in rats. Oxidation of [1-14C]palmitic acid, [1-14C]octanoic acid, and [1,4-14C]succinic acid allowed for the differentiation between carnitine-dependent long-chain fatty acid metabolism, medium chain fatty acid oxidation, and citric acid cycle activity, respectively. CAA, a metabolite of the anticancer drug ifosfamide, which may be responsible for ifosfamide-induced encephalopathy, inhibited palmitic acid metabolism but not octanoic or succinic acid oxidation, depleted hepatic glutathione, and stimulated bile flow. Methylene blue, which is clinically used to either prevent or reverse ifosfamide-associated encephalopathy, markedly stimulated palmitic acid oxidation either in the presence or absence of CAA, but did not affect the oxidation of octanoic and succinic acid or hepatic glutathione. Taken together, this study demonstrates that CAA inhibits palmitic acid metabolism. Methylene blue stimulates long-chain fatty acid oxidation, most likely by facilitating the translocation of fatty acids into mitochondria, and compensates for the CAA effect in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215658

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Authors:  Julio C Rojas; Aleksandra K Bruchey; F Gonzalez-Lima
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

3.  Dynamic analysis of metabolic effects of chloroacetaldehyde and cytochalasin B on tumor cells using bioelectronic sensor chips.

Authors:  E R Motrescu; A M Otto; M Brischwein; S Zahler; B Wolf
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

4.  Beneficial network effects of methylene blue in an amnestic model.

Authors:  Penny D Riha; Julio C Rojas; F Gonzalez-Lima
Journal:  Neuroimage       Date:  2010-11-16       Impact factor: 6.556

5.  Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model.

Authors:  Mohamed M Sayed-Ahmed; Amal Q Darweesh; Amal J Fatani
Journal:  Oxid Med Cell Longev       Date:  2010 Jul-Aug       Impact factor: 6.543

6.  Role of carnitine in cancer chemotherapy-induced multiple organ toxicity.

Authors:  Mohamed M Sayed-Ahmed
Journal:  Saudi Pharm J       Date:  2010-08-05       Impact factor: 4.330

Review 7.  Mechanisms underlying the anti-wasting effect of L-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies.

Authors:  Robert Ringseis; Janine Keller; Klaus Eder
Journal:  Eur J Nutr       Date:  2013-03-19       Impact factor: 5.614

8.  Mitigation of carbon tetrachloride-induced hepatic injury by methylene blue, a repurposed drug, is mediated by dual inhibition of GSK3β downstream of PKA.

Authors:  Hong Min Wu; Chan Gyu Lee; Se Jin Hwang; Sang Geon Kim
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

9.  Therapeutic approaches to delay the onset of Alzheimer's disease.

Authors:  Raj Kumar; Hani Atamna
Journal:  J Aging Res       Date:  2011-03-03

10.  l-carnitine and cancer cachexia: Clinical and experimental aspects.

Authors:  Renata Silvério; Alessandro Laviano; Filippo Rossi Fanelli; Marília Seelaender
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-01-26       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.